Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Melanoma

  Free Subscription


15.07.2019

1 Ann Surg Oncol
1 Biochem Biophys Res Commun
1 BMC Cancer
1 Br J Dermatol
2 Cancer
1 Clin Cancer Res
1 J Am Acad Dermatol
2 Lancet
2 Melanoma Res
1 Nat Med


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg Oncol

  1. MIURA JT, Zager JS
    ASO Author Reflections: Robotic Pelvic Lymph Node Dissection for Metastatic Melanoma-A Minimally Invasive Approach to a Difficult Problem.
    Ann Surg Oncol. 2019 Jul 8. pii: 10.1245/s10434-019-07612.
    PubMed     Text format    


    Biochem Biophys Res Commun

  2. MERAT R, Bugi-Marteyn A, Wrobel LJ, Py C, et al
    Drug-induced expression of the RNA-binding protein HuR attenuates the adaptive response to BRAF inhibition in melanoma.
    Biochem Biophys Res Commun. 2019 Jul 3. pii: S0006-291X(19)31309.
    PubMed     Text format     Abstract available


    BMC Cancer

  3. LOKHANDWALA PM, Tseng LH, Rodriguez E, Zheng G, et al
    Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
    BMC Cancer. 2019;19:665.
    PubMed     Text format     Abstract available


    Br J Dermatol

  4. OLSEN CM
    Reproductive factors and risk of melanoma: still unresolved.
    Br J Dermatol. 2019 Jul 9. doi: 10.1111/bjd.18136.
    PubMed     Text format    


    Cancer


  5. Erratum: Jeter JM, Bowles TL, Curiel-Lewandrowski C, et al. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019:125:18-44.
    Cancer. 2019;125:2706.
    PubMed     Text format    

  6. RULLI E, Legramandi L, Salvati L, Mandala M, et al
    The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32375.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  7. FIELD MG, Kuznetsov JN, Bussies PL, Cai L, et al
    BAP1 loss is associated with DNA methylomic repatterning in highly aggressive Class 2 uveal melanomas.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-19-0366.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  8. NALDI L, Cazzaniga S
    Mobile Teledermatology for Melanoma Detection. Response letter.
    J Am Acad Dermatol. 2019 Jul 3. pii: S0190-9622(19)32289.
    PubMed     Text format    


    Lancet

  9. THOMPSON JF, Friedman EB
    Appropriate excision margins for cutaneous melanomas.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31272.
    PubMed     Text format    

  10. UTJES D, Malmstedt J, Teras J, Drzewiecki K, et al
    2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial.
    Lancet. 2019 Jul 4. pii: S0140-6736(19)31132.
    PubMed     Text format     Abstract available


    Melanoma Res

  11. MIR R, Shaw HM, Nathan PD
    Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis.
    Melanoma Res. 2019;29:102-106.
    PubMed     Text format     Abstract available

  12. SEREMET T, Haccuria A, Lienard D, Del Marmol V, et al
    Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test.
    Melanoma Res. 2019;29:95-98.
    PubMed     Text format     Abstract available


    Nat Med

  13. ZAPPASODI R, Sirard C, Li Y, Budhu S, et al
    Rational design of anti-GITR-based combination immunotherapy.
    Nat Med. 2019;25:759-766.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: